Catalent Revenue 2012-2022 | CTLT
Catalent annual/quarterly revenue history and growth rate from 2012 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Catalent revenue for the quarter ending March 31, 2022 was $1.273B, a 20.89% increase year-over-year.
- Catalent revenue for the twelve months ending March 31, 2022 was $4.703B, a 25.17% increase year-over-year.
- Catalent annual revenue for 2021 was $3.998B, a 29.22% increase from 2020.
- Catalent annual revenue for 2020 was $3.094B, a 22.88% increase from 2019.
- Catalent annual revenue for 2019 was $2.518B, a 2.22% increase from 2018.
Catalent Annual Revenue
(Millions of US $) |
| 2021 |
$3,998 |
| 2020 |
$3,094 |
| 2019 |
$2,518 |
| 2018 |
$2,463 |
| 2017 |
$2,075 |
| 2016 |
$1,848 |
| 2015 |
$1,831 |
| 2014 |
$1,828 |
| 2013 |
$1,800 |
| 2012 |
$1,695 |
| 2011 |
$1,532 |
Catalent Quarterly Revenue
(Millions of US $) |
| 2022-03-31 |
$1,273 |
| 2021-12-31 |
$1,217 |
| 2021-09-30 |
$1,025 |
| 2021-06-30 |
$1,188 |
| 2021-03-31 |
$1,053 |
| 2020-12-31 |
$911 |
| 2020-09-30 |
$846 |
| 2020-06-30 |
$947 |
| 2020-03-31 |
$761 |
| 2019-12-31 |
$721 |
| 2019-09-30 |
$665 |
| 2019-06-30 |
$726 |
| 2019-03-31 |
$618 |
| 2018-12-31 |
$623 |
| 2018-09-30 |
$552 |
| 2018-06-30 |
$685 |
| 2018-03-31 |
$628 |
| 2017-12-31 |
$606 |
| 2017-09-30 |
$544 |
| 2017-06-30 |
$617 |
| 2017-03-31 |
$533 |
| 2016-12-31 |
$484 |
| 2016-09-30 |
$442 |
| 2016-06-30 |
$532 |
| 2016-03-31 |
$438 |
| 2015-12-31 |
$455 |
| 2015-09-30 |
$423 |
| 2015-06-30 |
$510 |
| 2015-03-31 |
$447 |
| 2014-12-31 |
$456 |
| 2014-09-30 |
$418 |
| 2014-06-30 |
$520 |
| 2014-03-31 |
$453 |
| 2013-12-31 |
$441 |
| 2013-09-30 |
$414 |
| 2013-06-30 |
|
| 2013-03-31 |
|
| 2012-06-30 |
|
| 2011-06-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Drug Manufacturing |
$17.531B |
$3.998B |
|
Catalent, Inc. is a renowned global provider of advanced delivery technologies as well as development and manufacturing solutions for drugs (protein, cell, and gene therapy biologics) and consumer health products.
|
